New drug targets tough cancers with KRAS G12V mutation
Disease control
Ongoing
This early-phase study tests a new drug called QTX3544, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change (KRAS G12V). The main goals are to check safety and find the right dose. About 237 adults with tumors that have…
Phase: PHASE1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC